Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine

Affiliations

• ¹ Department of Public Health, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan.
• ² Department of Allergy and Clinical Immunology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan.
• ³ Department of Infectious Diseases, Chiba University Hospital, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan; Chiba University Hospital COVID-19 Vaccine Center, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan.
• ⁴ Division of Laboratory Medicine, Chiba University Hospital, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan.
• ⁵ Clinical Research Center, Chiba University Hospital, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan.
• ⁶ Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan.
• ⁷ Department of Allergy and Clinical Immunology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan; Chiba University Hospital COVID-19 Vaccine Center, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan.
• ⁸ Department of Public Health, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan. Electronic address: onouchy@chiba-u.jp.